Loading...
XHKG
6118
Market cap47mUSD
Jun 13, Last price  
0.72HKD
1D
5.88%
1Q
-16.28%
Jan 2017
-37.93%
IPO
-78.25%
Name

Austar Lifesciences Ltd

Chart & Performance

D1W1MN
P/E
21.00
P/S
0.23
EPS
0.03
Div Yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
7.42%
Revenues
1.50b
-14.93%
705,153,000679,750,000627,544,000672,545,000546,933,000816,585,0001,049,021,0001,295,980,0002,015,028,0002,228,644,0001,763,734,0001,500,402,000
Net income
16m
P
53,571,00065,193,0006,384,000-18,670,000-54,085,000107,0008,091,00033,100,000277,300,00087,461,000-113,473,00016,079,000
CFO
99m
P
71,407,000-64,400,99961,526,000-30,462,000-6,171,000-77,598,00037,793,00052,224,000-103,451,000-37,926,000-62,649,00098,805,000
Dividend
May 19, 20150.05 HKD/sh

Profile

Austar Lifesciences Limited, an investment holding company, provides integrated engineering solutions to pharmaceutical manufacturers and research institutes in Mainland China and internationally. It operates through six segments: Liquid and Bioprocess System; Clean Room and Automation Control and Monitoring System; Powder and Solid System; GMP Compliance Service; Life Science Consumables; and Distribution and Agency of Pharmaceutical Equipment. The company offers liquid and bioprocess systems, including pharmaceutical water, and liquid preparation and bioprocess systems; powder and solid systems; clean utility equipment and systems; clean room, automation control, and monitor systems; and freeze-dryer, sterile filling, and visual inspection equipment. It also provides pharmaceutical process contamination control products; packaging and aseptic containment products; biosafety and lab animal equipment and consumables; laboratory one-stop solutions; and single-use bioprocess equipment and consumables. In addition, the company offers design, quality risk control, consulting, research and development support, process engineering, digitalization construction, after-sale, on-site, upgrading, relocation, and asset management services. Further, it is involved in the agency and distribution of pharmaceutical equipment, as well as provides assembly and pre-assembly services. The company was founded in 1991 and is headquartered in Shanghai, China.
URL
https://www.austar.com.cn/
IPO date
Nov 07, 2014
Employees
1,838
Domiciled in
CN
Incorporated in
KY

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
1,500,402
-14.93%
1,763,734
-20.86%
2,228,644
10.60%
Cost of revenue
1,491,810
1,784,005
2,149,411
Unusual Expense (Income)
NOPBT
8,592
(20,271)
79,233
NOPBT Margin
0.57%
3.56%
Operating Taxes
7,600
379
18,741
Tax Rate
88.45%
23.65%
NOPAT
992
(20,650)
60,492
Net income
16,079
-114.17%
(113,473)
-229.74%
87,461
-68.46%
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
345,612
333,213
233,604
Long-term debt
104,514
228,504
117,322
Deferred revenue
544
Other long-term liabilities
45,142
42,826
(38,284)
Net debt
222,040
315,842
117,298
Cash flow
Cash from operating activities
98,805
(62,649)
(37,926)
CAPEX
(69,235)
(117,327)
Cash from investing activities
4,430
(54,467)
(153,143)
Cash from financing activities
(101,323)
147,115
125,301
FCF
(5,785)
(8,555)
(214,663)
Balance
Cash
167,805
173,765
148,129
Long term investments
60,281
72,110
85,499
Excess cash
153,066
157,688
122,196
Stockholders' equity
793,468
391,825
544,027
Invested Capital
1,087,495
1,156,810
1,079,826
ROIC
0.09%
6.55%
ROCE
0.69%
6.39%
EV
Common stock shares outstanding
512,582
512,582
512,582
Price
0.57
-63.46%
1.56
-22.77%
2.02
-86.60%
Market cap
292,172
-63.46%
799,628
-22.77%
1,035,416
-86.60%
EV
516,271
1,117,930
1,139,351
EBITDA
61,698
25,328
115,772
EV/EBITDA
8.37
44.14
9.84
Interest
13,961
10,247
Interest/NOPBT
12.93%